Please assess the completion status of the following clinical trial:

Trial Title: Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 2 months (56 to 70 days) inclusive on the day of inclusion~* Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg~* Informed consent form signed by the parent(s) or other legal representative~* Able to attend all scheduled visits and to comply with all trial procedures~Exclusion Criteria:~* Participation in another clinical trial in the 4 weeks preceding the trial inclusion~* Planned participation in another clinical trial during the present trial period~* Congenital or acquired immunodeficiency, immunosuppressive therapy such as long term systemic corticosteroids therapy~* Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to the trial vaccine or a vaccine containing the same substances~* Chronic illness at a stage that could interfere with trial conduct or completion~* Blood or blood derived products received in the past or current or planned administration during the trial (including immunoglobulins).~* Any vaccination in the 3 weeks preceding the first trial vaccination.~* History of diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b infection (confirmed either clinically, serologically or microbiologically).~* Clinical or known serological evidence of systemic illness including Hepatitis B, Hepatitis C and/or Human Immunodeficiency Virus (HIV) infection~* Previous vaccination against the diphtheria, tetanus, pertussis, poliomyelitis diseases or Haemophilus influenzae type b infection with the trial vaccine or another vaccine.~* Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination~* History of/current major neurological diseases or seizures.~* Febrile illness (axillary temperature ≥ 38ºC) or acute illness on the day of inclusion.~* Known family history of congenital or genetic immuno-deficiency.

- Gender: ALL
- Minimum Age: 56 Days
- Maximum Age: 70 Days
- Healthy Volunteers: t

Study Arms:
- Study Group A (Type: EXPERIMENTAL): Participants will receive a single dose of DTacP-IPV//PRP T combined vaccine (PENTAXIM™) at age 2, 4 and 6 months.
- Study Group B (Type: ACTIVE_COMPARATOR): Participants will receive a dose of DTacP IPV combined vaccine (TETRAXIM™) and PRP-T vaccine (ActHIB™) at 2, 4, and 6 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).